Cyrela Brazil Realty S.A. ADS (CYRBY) Financials Nov 14,
Cyrela Brazil Realty S.A. ADS (CYRBY) Financials Nov 14, 2014, 8:10 p.m.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Cyrela Brazil Realty S.A. ADS
Fiscal year is January-December. All values BRL millions. 2009 2010 2011 2012 2013 5-year trend
Sales/Revenue 4.09B 4.89B 6.13B 5.63B 5.37B
Total Investment Income - - - - -
Sundry Revenue/Income 4.09B 4.89B 6.13B 5.63B 5.37B
Trading Account Income - - - - -
Trust Income, Commissions & Fees - - - - -
Commission & Fee Income - - - - -
Total Expense 3.32B 4.21B 5.61B 4.89B 4.61B
Total Interest Expense 156.18M 157.17M 243.42M 177.44M 142.49M
Depreciation & Amortization Expense 6.52M 8.89M 13.34M 122.73M 96.01M
Other Operating Expense (39.39M) (76.54M) 54.73M 43.71M 26.44M
2009 2010 2011 2012 2013 5-year trend
Operating Income 765.42M 676.81M 520.07M 743.08M 757.91M
Non-Operating Income (Expense) 256.54M 187.83M 279.58M 188.03M 186.91M
Non-Operating Interest Income 70.66M 93.83M 259.37M 161.17M 167.89M
Miscellaneous Non Operating Expense 157.17M 92.81M 20.21M 26.86M 19.01M
Equity in Affiliates (Pretax) 28.72M 1.2M - - -
Unusual Expense 80.93M 50.65M 20.7M 6.76M 5.02M
Pretax Income 941.03M 814M 778.95M 924.34M 939.8M
Income Taxes 114.13M 128.93M 188.21M 152.68M 135.89M
Income Tax - Current - Domestic 73.89M 106.79M 178.07M 183.13M 142.84M
Income Tax - Current - Foreign - - 0 0 0
Income Tax - Deferred - Domestic 40.23M 22.14M 10.14M (30.45M) (6.94M)
Income Tax - Deferred - Foreign - - 0 0 0
Income Tax Credits 0 0 0 0 0
Equity in Affiliates - - 1.45M 64.03M 90.09M
Other After Tax Income (Expense) 0 0 0 0 0
Consolidated Net Income 826.9M 685.07M 592.19M 835.69M 894M
Minority Interest Expense 97.55M 84.82M 94.02M 175.54M 175.17M
Net Income 729.35M 600.25M 498.17M 660.15M 718.83M
Extraordinaries & Discontinued Operations 0 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations 0 0 0 0 0
Net Income After Extraordinaries 729.35M 600.25M 498.17M 660.15M 718.83M
Preferred Dividends 0 0 0 0 0
Net Income Available to Common 729.35M 600.25M 498.17M 660.15M 718.83M
EPS (Basic) 1.77 1.46 1.24 1.61 1.77
Basic Shares Outstanding 411.47M 411.71M 403.16M 411.09M 407.26M
EPS (Diluted) 1.75 1.44 1.21 1.58 1.74
Diluted Shares Outstanding 415.61M 416.03M 411.08M 416.92M 414.15M
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Unexpected Turn of Events at Sea Now here's a gut-punch nobody saw coming. Borr Drilling Limited (NYSE and OSE: BORR) got hit hard when their Prospector 5 drilling rig went under the waves offshore Gabon. This ain't no desk job dilemma; we're talking about a real-life offshore catastrophe. It all went down on October 24, 2026, when the rig experienced a punch through...
Continue Reading
Turning Risk Management on Its Head Well, here's a company not just tinkering around the edges but flipping the script on Governance, Risk, and Compliance (GRC) with their latest rollout: DigitalXForce and its X-ROC. Yeah, it's yet another acronym to juggle, but don't roll your eyes just yet. This AI-driven beast isn't about occasional boardroom reports. No sir, it's a...
Continue Reading
Sowing Surgical Seeds in Lubbock In Lubbock, Texas, something meaningful unfolded—an event the big market players would hardly blink at, but a significant step for the future of medicine. Led by Dr. Thanapoom "Mo" Boonipat, the founder of FacePlus Plastic Surgery Institute, a unique suturing workshop provided premed students at Texas Tech University hands-on experience...
Continue Reading
A New Era in Lung Cancer Treatment? Sac-TMT, the novel antibody-drug conjugate (ADC), just might be shaking up the non-small cell lung cancer (NSCLC) treatment landscape, and boy, is it making waves. Just when you think you’ve seen it all, here comes sacituzumab tirumotecan (sac-TMT), offering a glimmer of hope for patients whose treatment options have dwindled after...
Continue Reading
Revving Up for Africa Alright, gearheads and number-crunchers, strap in. BAIC FOTON is making headlines again, and this time they’re zooming right into Africa—like they're claiming pole position on a circuit that's been ignored by many. They’re calling it a “Drive to Great!” but what does that mean for us investors who aren’t just in it for the entertainment?...
Continue Reading
Fluence Energy Faces a Securities Fraud Challenge It's like watching a slow-motion train wreck. Fluence Energy, Inc. (NASDAQ: FLNC) now finds itself in the crosshairs of a securities fraud class action lawsuit. Apparently, someone was playing fast and loose with the truth concerning their financial guidance. The period in question stretches from November 24, 2025, to...
Continue Reading
Kicking Off Early Black Friday with Dash Cam Bargains In a bid to stay ahead of the holiday shopping rush, Vantrue announced its early Black Friday campaign with a range of discounts designed to capture the interest of road warriors and casual drivers alike. From November 1 to November 21, 2026, Vantrue is inviting bargain hunters to explore their offerings—culminating...
Continue Reading
New Data Unveiling Potential Shifts in NSCLC Treatment Man, if there's one thing the oncology world craved, it's progress against KRAS G12C-mutant non-small cell lung cancer (NSCLC). We're talking about a challenge as tough as a two-dollar steak. But hey, Eli Lilly's (NYSE:LLY) putting some serious cards on the table with olomorasib, and folks at the ESMO 2026 Congress...
Continue Reading
Are Slim iPhone Cases Really Protecting Your Investment? Anyone who's dropped a brand-new phone knows the pain of watching your investment smack the concrete. But hey, welcome to 2026, where Consumer365's latest rundown on iPhone protective gear turns the spotlight on TORRAS. These folks grabbed attention with their Q3 Air and Q3 Air Pro cases, crafted for iPhone 18 Pro...
Continue Reading
Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...
Continue Reading
Top 5 Most Recently Viewed Articles
Grand Circle Cruise Line Recognized Among the Best Grand Circle Cruise Line (GCCL) recently earned the impressive title of #2 Best River Cruise Line in the Travel + Leisure's 2025 World's Best Awards. This accolade showcases the hard work and dedication of the teams and crew members who make each journey remarkable along Europe’s scenic rivers. Celebrating a Special...
Continue Reading
Lancaster Resources Secures Approval for Exploration License Vancouver-based Lancaster Resources Inc. (CSE:LCR) (OTC:LANRF) (FRA:6UF0) is pleased to announce a significant milestone in its gold exploration journey. The company has received confirmation of an Exploration License for the Lake Cargelligo Gold Project from the State of New South Wales. Covering an impressive...
Continue Reading
Understanding the Vitrectomy Devices Market Growth The vitrectomy devices industry has become increasingly vital in treating various eye-related disorders, with significant growth projected in the coming years. By focusing on technological advancements and heightened awareness of eye health, the market is set to expand impressively. According to a recent report, the...
Continue Reading
Understanding RDG Mining's Latest Offerings In recent times, the popularity of cryptocurrency has surged significantly, with platforms like RDG Mining capitalizing on this trend. RDG Mining is a leading cloud mining service based in the UK that has captured the interest of over 7.5 million users globally, particularly with the rise in various cryptocurrencies, including...
Continue Reading
Revisions to Financial Reporting and Calendar The board of Pharma Equity Group A/S has recently made the strategic decision to submit only half-yearly financial reports moving forward. This adjustment reflects a shift in focus towards more impactful reporting. As a result, the financial calendar for 2025 has been updated to better align with these new reporting practices....
Continue Reading